WT Faba Catalyst: Bridging Science and Business in Life Sciences WT Faba Catalyst, a pioneering initiative of the ‘Whale Tank FABA Life Science Fund’, is redefining how Indian innovation in life sciences reaches global markets. Born from the vision of seasoned veterans and mission-driven leaders, it provides not just capital—but clarity, confidence, and capability—to life science startups poised to transform human health, agriculture, and nutrition. With ‘strategic partnerships’ that already include Revelations Biotech’, ‘ATGC Biotech’, and ‘Utopia Therapeutics’, Whale Tank has become a cornerstone of support for startups navigating the demanding path from the lab bench to the marketplace. **Our Origin Story: Built by Experts, For Innovators** Whale Tank was founded by a group of **industry veterans** with a shared mission: **to resolve the systemic challenges faced by deep-science startups** in India and the global South. From their work in pharma, agritech, biotech, and venture capital, these leaders understood a core reality—**innovation alone isn’t enough**. Scientific breakthroughs often stall due to fragmented business planning, unclear market access, and limited investor guidance. To change this narrative, Whale Tank was established as a **science-first catalyst** with business-savvy DNA, offering tailored support to help life sciences ventures scale impact and unlock commercial potential. — ### **Strategic Partnerships that Amplify Innovation** Whale Tank doesn’t just fund ideas—it backs missions. Our growing portfolio features strategic collaborations with: #### **Revelations Biotech** An innovative force in **natural sweeteners and prebiotics**, Revelations is redefining food and nutrition science with cutting-edge products like **Fructooligosaccharides (FOS)**, **Brazzein**, and **Allulose**. Whale Tank invested $2 million in this high-growth venture, facilitating: – Global partnerships with **Kellogg’s**, **PepsiCo**, **Nestlé**, **Britannia**, and **Unilever** – Scale-up of production infrastructure (fermentation and spray-drying facilities) – Market penetration across **North America**, **Europe**, and **Asia-Pacific** Revelations reflects Whale Tank’s belief that **science-driven startups can reshape public health, when supported with strategic capital and mentorship**. #### **ATGC Biotech** As a biotechnology pioneer in **sustainable agriculture and pest management**, ATGC has developed eco-friendly technologies that improve crop yields while minimizing environmental impact. Under the leadership of **Dr. Markandeya Gorantla** and **Rolando Alegria**, ATGC: – Specializes in bio-rational solutions using behavioral ecology using pheromone based mating disruption technology – Has filed multiple patents and gained regulatory approvals – Has scaled distribution through private sector and public procurement models Whale Tank and ATGC share a common DNA: commitment to **science-backed sustainability** and **farm-to-fork innovation**. #### **Utopia Therapeutics** Founded by **Dr. Uday Saxena**, Utopia is a drug discovery and therapeutics startup with a focus on **neurodegenerative and metabolic disorders**. Utopia’s leadership—rooted in big pharma —guides startups in navigating clinical validation, regulatory frameworks. Whale Tank’s synergy with Utopia provides its portfolio companies with strategic insights into **drug development lifecycles**, **FDA compliance**, and **venture pathways. — ### **Mission-Driven Investment Philosophy** At its core, **Whale Tank is a catalyst, not just a fund**. Our mission is to: – **Fuel Innovation** through strategic, milestone-based capital – **Bridge Science and Business** with real-world execution models – **Accelerate Commercialization** across agriculture, biotech, diagnostics, and therapeutics – **Empower Indian Science** by building platforms for global impact We understand that scientific excellence must be matched with **business discipline** and **market readiness**—so we provide both. — ### **Our Values: The Whale Tank Ethos** Our approach is guided by unwavering principles that reflect our commitment to lasting impact: #### Integrity as a Foundation of Trust We uphold the highest standards of transparency and ethical governance, ensuring alignment between founders, investors, and stakeholders. #### Collaboration for Greater Innovation We believe that breakthrough ideas flourish in collaborative ecosystems. Whale Tank connects innovators with world-class mentors, global partners, and technical experts to foster innovation at scale. #### Commitment to Continuous Improvement The life sciences landscape evolves fast—and so do we. From regulatory updates to tech advancements, we equip our portfolio with the latest tools to stay competitive and compliant. — ### **Our Differentiators: The Whale Tank Advantage** Whale Tank delivers a full-spectrum support model that integrates: | Service | Description | |——–|————-| | **Visionary Capital** | Flexible seed and Series A funding, aligned to product-market readiness | | **Mentorship Network** | Access to 50+ domain experts in biotech, drug development, clinical trials, and regulatory science | | **Business Alchemy** | Go-to-market, licensing, pricing, and distribution support | | **IP & Legal Advisory** | End-to-end guidance on patents, exclusivity, and data rights | | **Infrastructure Scaling** | Support for facility design, tech transfer, and manufacturing scale-up | | **Exit Strategy Navigation** | IPO prep, M&A, and secondary share sale pathways | This framework has empowered startups to **reduce time-to-market**, **attract global partners**, and **build sustainable revenue models**. — ### **Governance, Structure & Investor Value** ### **Impact Snapshot: Delivering Results that Matter** Beyond numbers, our true impact is in lives touched, diseases addressed, and ecosystems enhanced. Whether it’s **healthy nutrition**, **sustainable farming**, or **precision medicine**, Whale Tank empowers science that serves society. — ### **Vision for the Future: Scaling Science for Global Good** Whale Tank is now building a **pipeline of next-gen ventures** across: – **Synthetic Biology** – **Microbiome Therapeutics** – **Agricultural Biocontrols** – **Climate-Resilient Crop Technologies** – **Affordable Diagnostics and Functional Foods** Our goal is to create **India’s first science-forward unicorns** that are not just financially successful—but mission-aligned and globally relevant. — ### **Join the Movement: Let’s Build the Future of Life Sciences** We invite researchers, entrepreneurs, and investors to partner with us. Whether you’re developing the next sugar alternative, breakthrough therapy, or agricultural bioinnovation—**Whale Tank will help you get there.** For partnerships and investment inquiries, contact: **Dr. Jagadeesh Gandla** Chief Operating Officer, Whale Tank FABA Life Science Fund **info@whaletank.in** — **WT Faba Catalyst isn’t just a fund. It’s a movement.** A movement to **empower ideas**, **bridge discovery with delivery**, and **build India’s life sciences future**—one transformative startup at a time. Let’s catalyze the change.
Wacker Biotech
WACKER BIOTECH is “THE MICROBIAL CDMO” – your partner of choice for process development and contract manufacturing of biopharmaceuticals (proteins, vaccines, live microbial products, plasmid DNA (pDNA)) using microbial hosts. Additionally, WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation, the nucleic acid expertise of Wacker Biotech combined with the lipid expertise of our partner CordenPharma ensures the best possible results for each of our client’s mRNA-focused projects. WACKER BIOTECH’s integrated service portfolio covers molecular biology, process / analytical development as well as GMP manufacturing of biologics for clinical and commercial supply. WACKER BIOTECH operates four state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands. Manufacturing lines are equipped with stainless steel fermentation vessels from 350 to 1500 liter as well as single-use bioreactors. Matching primary recovery, downstream and Fill & Finish capabilities are available to suit various clients’ needs across the development path (BSL 1 and 2). Additionally, a GMP cell-bank suite enables independent cell-bank production and storage capacity for client cell banks. In 2022 the German government selected Wacker Biotech and CordenPharma as joint bidders for the stand-by production of vaccines based on mRNA. Therefore, WACKER is now building a state-of-the-art mRNA competence and manufacturing center at its existing Halle, Germany site to complement its other existing sites in Jena, Germany, Amsterdam, the Netherlands and San Diego, California. The new capabilities at Wacker Biotech Halle will support end-to-end manufacturing of plasmid DNA, mRNA and LNP formulation under one roof. WACKER BIOTECH holds biomanufacturing certificates from the relevant authorities for all sites and follows the ICH Q7A guidelines for GMP-compliant production of biologics. The GMP production facilities in the Netherlands and Germany are approved by the EMA, U.S. FDA and/or ANVISA for commercial manufacturing. The WACKER BIOTECH U.S. site is currently preparing for a U.S. FDA inspection. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of Munich-based Wacker Chemie AG. | WACKER BIOTECH is the CDMO partner of choice for process development and manufacturing of biopharmaceuticals (therapeutic proteins, vaccines, live biotherapeutic products) based on microbial systems and for the entire manufacturing chain of pDNA, mRNA and lipid nanoparticle formulations. Our clients benefit from our decades of experience in complex protein-based therapeutics, vaccines, and specialty chemicals sectors, including partnering with the German government to respond to the Covid-19 pandemic. WACKER BIOTECH operates five state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands. Manufacturing lines are equipped with stainless steel fermentation vessels from 350 to 1500 liter as well as single-use bioreactors. Matching primary recovery, downstream and Fill & Finish capabilities are available to suit various clients’ needs across the development path (BSL 1 and 2). WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation, the nucleic acid expertise of Wacker Biotech combined with the lipid expertise of our partner ensures the best possible results for each of our client’s mRNA-focused projects. In Amsterdam, NL, we jump-started mRNA manufacturing during the COVID-19 pandemic, making us a leading CDMO with hands-on GMP manufacturing experience of mRNA-based therapies, including validation GMP runs. With the addition of another cutting-edge competence center for mRNA actives in Halle, Germany, we have increased our RNA product manufacturing and LNP formulation capacity. In this dynamic field of advanced therapies, you will benefit from experienced, reputable partners validated by the German government. In close collaboration with universities and research institutions, WACKER’s corporate R&D team of over 200 researchers continuously develops new production platforms and technologies for all types of biopharmaceuticals, including pDNA, mRNA and LNPs. Competitive, outstanding solutions are our trademarks. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of Munich-based Wacker Chemie AG. | Wacker Biotech is the expert biologics CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid and template DNA as a starting material for mRNA through the IVT of mRNA to lipid nanoparticle (LNP) formulation. We have the capability to produce at diverse scales up to 1500 L and recently quadrupled our mRNA production capacity with the completion of a new mRNA competence center in Halle, Germany. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization. We operate five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and the US (San Diego). Complementing our bioprocess development and manufacturing experts at these four sites is a team of dedicated research scientists leading continuous innovations and collaborations at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading chemistry advances. We have 30+ years of experience developing biologics to advance human and animal health. | Wacker Biotech is the expert biologics CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid DNA as a starting material for RNA, to the IVT of RNA, to lipid nanoparticle (LNP) formulation. We also produce >97% supercoiled plasmids for AAV and LV delivery, and for direct application. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization. Our global footprint encompasses five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and USA (San Diego), able to produce at diverse R&D, HQ and GMP grades, with scale-up to 1500 L. Complementing our bioprocess development and manufacturing experts at these sites is a team of dedicated research scientists leading continuous innovations and collaborations, and also providing nucleic acid contract research services, at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading biochemistry advances. We have 30+ years of experience manufacturing biologics to advance human and animal health.
Viruj Group
Viruj Group was established in 2014 by a group of young & experienced professionals with the specific objective to develop & produce complex, small to large volume, technology driven Intermediates/ API at competitive prices, thus providing the critical India advantage for a CRO/ NCE Molecules across the world. We are a partner for various Innovator companies to supply High Quality API’s /Intermediates & Fine chemicals at competitive prices Complying with Regulatory Requirements. Our Experienced R&D team – well qualified & equipped to develop most complex Intermediates/ APIs and expertise to handle wide range of chemical reactions. Manufacturing capabilities ranging from gram level to multiple ton lots. Strong Intellectual Property Management and Regulatory back up & Absolute assurance of best quality APIs. Expertise in the development of novel, non-infringing and cost-effective API’s Speed to market for customers and support the NCE / Dossier by time bound development. Timely delivery and prompt response to all queries of the customers CRO/CDMO – We intend to take up any projects in this area working closely with you team for small or big enquiries, we have a dedicated team working in this area. Flow Chemistry – Our process lab is established with a motto to make API / Intermediates and Fine Chemicals in Flow chemistry mode as far as the molecule permits, we have established few global business and making R&D/ Pilot scale modules and converting existing batch chemistry to flow chemistry way. We are ready to take up projects for any commercial scale products on Pharma/ Agro/Fine Chemicals space.
Valpharma International S.p.A.
Valpharma Group SpA is an European pharmaceutical company leader in pharmaceutical development and contract manufacturing of oral FDF solid dosage medicines and nutraceuticals, with more than 45 years expertise in commercial supply in more than 70 markets. Our plants are authorized to manufacture (IMP and commercial) powders, granulates, film-coated- not film-coated tablets (FDF), pellets bulk or capsules (FDF). Dossiers: Melatonine ER Apixaban IR Gliclazide SR Diltiazem SR In development Semaglutide IR Upadacitinib ER Mirabegron ER
UNITHER PHARMACEUTICALS
Unither Pharmaceuticals is a pharmaceutical subcontractor specializing in the development and manufacturing of unit-dose and multidose liquid formulations (including eye drops, saline solutions, asthma medications in BFS unit doses, and oral liquid stick-packs) for originator pharmaceutical companies and generic manufacturers. With 2,300 employees and eight manufacturing plants across France, the United States, Brazil and China, as well as an R&D center in France, Unither Pharmaceuticals reported sales of EUR 522 million in 2024. www.unither-pharma.com
UDELA
Udelá is a regulatory consulting company. Udelá was created by a group of highly qualified professionals in the regulatory affairs field, with more than 15 years of experience, for medicines, medical devices, food, dietary supplements and cosmetics. Udelá is located in Mexico City, and has presence in Central and Latin America. Objectives – Provide technical and regulatory support, which accelerates the access of medicines, medical devices, food, dietary supplements and cosmetics on the market to improve the health of the population, through regulatory standard compliance and a build trust with regulatory agencies. – Bridge the knowledge gap of our clients in regulatory affairs to improve the communication with the regulatory agencies – Enhance processes of marketing authorization of medicines and medical devices (pre-marketing, registration and post marketing) to ease the access on the market and improve its maintenance – Active collaboration with our clients to generate better regulatory strategies to reduce timelines and optimize resources Services – Dossier compilation and evaluation o Medical Devices o New chemical entities/ New Molecules o Generics / Hybrids o Biotechnological products and Biosimilars o Vaccine o Biologics and blood derivative products – Design of regulatory strategies o Regulatory Due diligence o Feasibility studies for medicines and medical devices registration o Strategies for maintenance of existing and forthcoming products – Hosting & Testing services – Good manufacturing practices / License – Advertising – Translations – KOL feedback | At Udelá, we empower healthcare companies—whether local or international, emerging or established—to enter and expand in the complex markets of Mexico and Latin America. With over 5 years of experience, we specialize in regulatory intelligence, market entry strategies, and end-to-end support for pharmaceutical products, biotechnology, medical devices, cosmetics, food supplements, and more. We understand that navigating the ever-evolving regulatory frameworks of Latin American countries can be overwhelming if not approached strategically. That’s where we come in. Our multidisciplinary team of consultants combines in-depth knowledge of regional regulatory environments with strategic execution capabilities. We act with precision, pragmatism, and agility to deliver timely and compliant market access solutions. Our key services include: Regulatory and strategic consulting for healthcare products Legal representation and in-country regulatory agent services Warehousing and distribution infrastructure compliant with national regulations With headquarters in Mexico City and operations in Colombia, Brazil, Chile, Perú, Ecuador, Uruguay, Paraguay, Bolivia, Argentina and Central America, we offer both local expertise and regional reach. Whether you’re launching a generic, innovative, or biologic product—or seeking to expand your presence across LATAM—Udelá is your trusted partner in achieving regulatory clarity and commercial success. Where do you want to go next? Let’s go beyond, together.
TrialAssure
TrialAssure® delivers AI Enabled, Human Driven™ solutions for data, document, and image anonymization, medical writing, and clinical trial transparency. With this approach, we help life sciences be efficient, enhance disclosure, and protect patient privacy. Please reach out if you are looking for an AI-enablement partner.
TLC BioSciences
TLC BioSciences is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC’s deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX® active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC was consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations every year until the company went private in 2021. | TLC BioSciences is a late clinical stage specialty pharmaceutical company. At TLC, we are dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC is dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management. | TLC BioSciences is a clinical‑stage biotechnology company advancing lipid‑engineered medicines across metabolic, orthopedic, and immune‑cell therapy. Our proprietary LipAD® family of platforms—including BioSeizer® sustained‑release technology, NanoX® active drug‑loading systems, and next‑generation targeted lipid nanoparticles (tLNP)—enables long‑acting, targeted, and programmable delivery for a wide range of therapeutic modalities. With a robust pipeline spanning once‑monthly GLP‑1 therapy (TLC518), late‑stage non‑opioid pain programs, and in‑vivo CAR‑T applications, TLC is committed to delivering medicines with improved efficacy, safety, and accessibility.
TEDOR Pharma Services
Tedor Pharma Services is a reliable, US-based CDMO with over 20 years of experience in solid dosage forms, headquartered in Cumberland, RI on the Rhode Island- Massachusetts border an hour drive from Boston. Our expert team provides guidance and flexible, end-to-end outsourcing solutions for small and dry powder large molecule drug product development. We offer manufacturing from clinical phase I through large-scale commercial production for worldwide clients, utilizing decades of industry knowledge and quality manufacturing experience to help bring your product to market. As a committed CDMO, Tedor Pharma Services has invested in our facility’s infrastructure and expert staff to ensure customer success, facilitating easy tech transfers with our robust QMS and excellent regulatory track record. We partner with companies of all sizes, from those with diverse commercial portfolios to virtual companies navigating regulatory filings (IND, NDA, ANDA) or post-ANDA acquisition. Tedor delivers high-quality, cost-competitive GMP manufacturing services, is DEA licensed for controlled substances (CI-CV), and specializes in small batch and complex product formulation. Our comprehensive solutions encompass: Formulation & Process Development: Collaborative and transparent approach to address complex delivery profiles, including precise release mechanisms, API combinations, and challenging APIs. We support products from early clinical phases to commercial scale, tackling tough formulation and manufacturing challenges for diverse platforms like tablets, capsules, high/low potency, modified/extended release, powders, granulations, beads, bi-layer tablets, extrusions, slugs, liquids, creams, lotions, suppositories, hollow core, multi-fill capsules, enteric-coated, and effervescent formulations. Analytical Services: Rigorous capabilities essential for drug product development, reproducibility, and quality assurance from pre-formulation to commercialization. Our robust services support product development, process optimization, regulatory filing, and quality assurance, including material characterization, stability assays, thermal analysis, particle size, dissolution studies, solution stability, filter/flush evaluation, limits of detection/quantitation, linearity/range, specificity (including forced degradation), and product release testing. Clinical Trial Supply Services: Deep commitment to supporting each phase of clinical development with high flexibility for shifting timelines and extensive experience in storing and shipping investigational drug products. We provide comprehensive support for regulatory submissions, utilizing GMP and GCP approaches to safeguard IDP supply with tailored tooling and manufacturing to match product characteristics. Commercial Manufacturing: Full product lifecycle support for solid dose manufacturing, from development to clinical and commercial scales, with straightforward tech transfer processes. We handle diverse solid dose complexities, including tablets, capsules, single & multi-layer tableting, immediate and modified-release formulations, extended-release, DEA schedules I-V, high-potency, poorly soluble/variable APIs, multi-API products, pelletized products, various coatings, abuse deterrent, dry large molecule, encapsulation, powder biologics, and orphan drug small-batch manufacturing. We offer primary and secondary commercial source manufacturing options for security of supply.
TaiMed Biologics
TaiMed Biologics, founded in 2007, is a leading biopharmaceutical developer and manufacturer in Taiwan. We have extensive monoclonal antibodies (mAb) development and manufacturing experiences and have successfully developed and commercially launched the first and only mAb for HIV treatment in the US and Europe (Brand name: Trogarzo®). We are proud to offer Contract Development and Manufacturing Organization (CDMO) services for biopharmaceutical companies to propel your important monoclonal antibody molecules from development to market launch. | TaiMed Biologics & Orient EuroPharma — Your Trusted Partners in Biologics and CDMO Services TaiMed Biologics (TaiMed) is a leading biopharmaceutical company specializing in the development and manufacturing of innovative biologics, with a strong focus on anti-HIV therapies. Our Key Strengths Include: – First-in-Class Innovation: Developer of Trogarzo® (ibalizumab), the world’s first long-acting monoclonal antibody for HIV, approved by the US FDA and EMA in 2018 and 2019. – Next-Gen HIV Therapies: Advancing long-acting monoclonal antibodies for HIV treatment and prevention. – Clinical-Stage Leadership: Leading candidate TMB-365/380 received Fast Track Designation from the US FDA in 2023 and has successfully completed Phase 2a, showing promising potential as a more confirming and durable HIV therapy. – Partnering Opportunities: Actively seeking global licensing and co-development partnerships with companies focused on HIV therapy. – CDMO Services: Leveraging decades of antibody development experience, TaiMed now offers end-to-end CDMO solutions, from early-stage development through to commercial manufacturing. This year, TaiMed is proud to co-exhibit with our long-term partner, Orient EuroPharma (OEP), to present integrated, high-quality biomanufacturing solutions that meet global standards. About Orient EuroPharma (OEP) Founded in 1982, Orient EuroPharma (OEP) is a Taiwan-based multinational pharmaceutical company specializing in prescription medicines, nutricare, and anti-aging products. OEP also offers comprehensive CDMO services, providing expertise from formulation development to commercial-scale finished product manufacturing. OEP’s CDMO capabilities include: – Formulation Development: Expertise in controlled-release formulations – Oral Dosage Manufacturing: Tablet, Capsule (granule/pellets/semi-solid/liquid filling) – Injectable Manufacturing: Liquid and lyophilized vials for high potency, cytotoxic and non-cytotoxic product Why Partner with OEP? – Regulatory Excellence: 15+ successful IND submissions in the U.S., China, and Taiwan; NDA projects ongoing – U.S.-Based R&D (San Diego Lab): Local formulation development & small-scale batch production for faster collaboration – Advanced Capsule Technology: Specialized in semisolid/liquid filling and banding for enhanced drug stability -Flexible Manufacturing Scale: Seamless transition from small-batch IND to large-scale NDA production – Quality Certification: Facilities certified by US FDA, PIC/S GMP, TGA, and MHRA With a strong track record of innovation, regulatory success, and manufacturing quality, TaiMed and OEP together offer a powerful CDMO partnership to support your drug development and commercialization goals. Visit us at our booth to explore collaborative opportunities!